Key takeaways:

  • Building on the resounding success of the ESC Council of Cardio-Oncology’s inaugural conference in 2025, ESC Cardio-Oncology 2026 will take place in Vienna from 19 to 20 June.
  • ESC Cardio-Oncology 2026 brings together global specialists across cardiology, oncology, haematology, radiotherapy and related areas to discuss how heart-related risks can be reduced in cancer patients and survivors.
  • Collaboration is a key driver to improve patient outcomes, and the congress serves as a forum to help shape the future of this rapidly evolving field.

Sophia Antipolis, France – 9 June 2026: Following the resounding success of the inaugural conference in 2025, ESC Cardio-Oncology 2026, organised by the European Society of Cardiology’s Council of Cardio-Oncology, will take place in Vienna, Austria, from 19 to 20 June.

Cardiovascular toxicity is recognised as a major side effect of anticancer therapies.[1] “Cardio-oncology aims to help patients receive the most effective cancer treatment as safely as possible, by preventing, detecting and managing cardiovascular disease and cardiovascular complications during cancer therapy and throughout survivorship,” explained Dr. Teresa Lopez Fernandez, Chair of the ESC Council of Cardio-Oncology and ESC Cardio-Oncology 2026 Conference Co-Chair. At the core of cardio-oncology is an interdisciplinary team involving oncologists, haematologists, radiation oncologists, cardiologists, specialist nurses and pharmacists. “Key to advancing the field is the continuation of collaborative international research and also the formation of new connections between industry partners and regulators to improve the safety of cancer treatments,” added Dr. Lopez Fernandez. “This is why the conference is so important: it serves as a forum to initiate conversations and discuss issues – including challenging ones – affecting our patients daily.”

As such, the conference programme includes 70 scientific sessions – from practical seminars and clinical cases to debates and abstract sessions – reflecting real-world practice and cutting-edge research. Importantly, patient participants will share their personal experiences in a number of sessions alongside the scientific content.

The programme includes four joint sessions with oncology societies: the European Society for Medical Oncology (ESMO), European Hematology Association (EHA), European Society for Radiotherapy and Oncology (ESTRO) and International Cardio-Oncology Society (IC-OS). “The conference offers a common space where oncology societies can share new data and insights. We will discuss the key management strategies that cardio-oncology teams should try to implement and also describe future needs in terms of the clinical trials required to advance care,” noted Dr. Alexander Lyon, ESC Cardio-Oncology 2026 Conference Co-Chair.

“Cardio-oncology is a relatively new cardiovascular subspecialty, and multidisciplinary teams are now familiar with common issues encountered in daily practice. The most appropriate clinical management of the less frequent complex cases is often more challenging; the best approaches are evolving, balancing cardiac risks with oncology priorities, and the debate sessions between multiple disciplines will spark stimulating conversations. I am also looking forward to the ‘Virtual Guidelines’ session, which was a highlight last year, engaging the entire audience to vote on potential new cardio-oncology guideline recommendations,” added Dr. Lyon.

Dr. Lopez Fernandez concluded: “ESC Cardio-Oncology 2026 is more than a conference – it's a movement.  It is very exciting to bring everyone together to share the latest research results, discuss complex cases and plan research endeavours to enhance future management and drive the field forward.”

ENDS